Dysregulated circulating miRNAs in preeclampsia

  • Authors:
    • Carine Munaut
    • Linda Tebache
    • Silvia Blacher
    • Agnès Noël
    • Michelle Nisolle
    • Frédéric Chantraine
  • View Affiliations

  • Published online on: October 14, 2016     https://doi.org/10.3892/br.2016.779
  • Pages: 686-692
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Preeclampsia (PE) is a pregnancy-related disease with potentially severe consequences with respect to foeto-maternal morbidity and mortality. However, the molecular pathogenesis of PE remains largely unknown. Recent reports have shown that microRNAs (miRNAs or miRs) may play important roles in the development of PE. Analysing the miRNAs in sera from preeclamptic women may improve our understanding of the pathophysiological mechanisms of the disease. The aim of this retrospective study was to identify whether circulating miRNAs were differentially expressed in PE patients compared with controls. Serum samples from 23 women who developed PE were compared with samples from 44 pregnant controls. Seventeen circulating miRNAs previously described in PE were chosen for evaluation of their expression by reverse transcription quantitative polymerase chain reaction (RT‑qPCR). In the maternal serum, the miR‑210‑3p, miR‑210‑5p, miR‑1233‑3p, and miR‑574‑5p levels were found to be significantly higher in the PE patients than in the controls (P<0.05). Using a logistic regression model, we evaluated the discriminant power of those differentially expressed miRNAs, and the combination of miR‑210‑5p and miR‑574‑5p yielded an area under the curve of 0.7223 for discriminating PE patients from the controls. In conclusion, the fact that four circulating miRNAs (miR‑210‑3p, miR‑210‑5p, miR‑1233‑3p, and miR‑574‑5p) were differentially expressed in the sera of women who developed PE compared with controls confirms the possible pathophysiological role of miRNAs in PE.

References

1 

American College6 of Obstetricians and Gynecologists, . Task Force on Hypertension in Pregnancy: Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 122:1122–1131. 2013.PubMed/NCBI

2 

Redman CW and Sargent IL: Latest advances in understanding preeclampsia. Science. 308:1592–1594. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 33:130–137. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 183:S1–S22. 2000. View Article : Google Scholar

5 

Sibai B, Dekker G and Kupferminc M: Pre-eclampsia. Lancet. 365:785–799. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Huppertz B: Placental origins of preeclampsia: Challenging the current hypothesis. Hypertension. 51:970–975. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Foidart JM, Noël A, Chantraine F, Lorquet S, Petit P, Munaut C, Berndt S, Pequeux C and Schaaps JP: Defective placental implantation and its effects on maternal endothelial function. Bull Acad Natl Med. 193:1059–1064; discussion 1064–1066, 1067–1068. 2009.(In French). PubMed/NCBI

8 

Foidart JM, Schaaps JP, Chantraine F, Munaut C and Lorquet S: Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immunol. 82:106–111. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Redman CW, Sargent IL and Staff AC: IFPA Senior Award Lecture: Making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta. 35:S20–S25. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F and Foidart JM: Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod. 23:1407–1415. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Roberts JM and Hubel CA: The two stage model of preeclampsia: Variations on the theme. Placenta. 30:(Suppl A). S32–S37. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Redman CW and Sargent IL: Immunology of pre-eclampsia. Am J Reprod Immunol. 63:534–543. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Dechend R and Staff AC: Placenta messages to the mother: Not just debris. Hypertension. 59:191–193. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Lai EC: Micro RNAs are complementary to 3 UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12 body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Ong SG, Lee WH, Kodo K and Wu JC: MicroRNA-mediated regulation of differentiation and trans-differentiation in stem cells. Adv Drug Deliv Rev. 88:3–15. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Miura K, Miura S, Yamasaki K, Higashijima A, Kinoshita A, Yoshiura K and Masuzaki H: Identification of pregnancy-associated microRNAs in maternal plasma. Clin Chem. 56:1767–1771. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Tsochandaridis M, Nasca L, Toga C and Levy-Mozziconacci A: Circulating microRNAs as clinical biomarkers in the predictions of pregnancy complications. BioMed Res Int. 2015:2949542015. View Article : Google Scholar : PubMed/NCBI

20 

Li H, Ge Q, Guo L and Lu Z: Maternal plasma miRNAs expression in preeclamptic pregnancies. Biomed Res Int. 2013:9702652013.PubMed/NCBI

21 

Wu L, Zhou H, Lin H, Qi J, Zhu C, Gao Z and Wang H: Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies. Reproduction. 143:389–397. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Gunel T, Zeybek YG, Akçakaya P, Kalelioğlu I, Benian A, Ermis H and Aydınlı K: Serum microRNA expression in pregnancies with preeclampsia. Genet Mol Res. 10:4034–4040. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Ura B, Feriotto G, Monasta L, Bilel S, Zweyer M and Celeghini C: Potential role of circulating microRNAs as early markers of preeclampsia. Taiwan J Obstet Gynecol. 53:232–234. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M and Sun S: Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 56:1830–1838. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

26 

Kok MG, Halliani A, Moerland PD, Meijers JC, Creemers EE and Pinto-Sietsma SJ: Normalization panels for the reliable quantification of circulating microRNAs by RT-qPCR. FASEB J. 29:3853–3862. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Hanley JA and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:29–36. 1982. View Article : Google Scholar : PubMed/NCBI

28 

Zhao Z, Moley KH and Gronowski AM: Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases. Clin Biochem. 46:953–960. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Chen Y, Gelfond JA, McManus LM and Shireman PK: Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics. 10:4072009. View Article : Google Scholar : PubMed/NCBI

30 

Sato F, Tsuchiya S, Terasawa K and Tsujimoto G: Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One. 4:e55402009. View Article : Google Scholar : PubMed/NCBI

31 

Roberts TC, Coenen-Stass AML and Wood MJA: Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum. PLoS One. 9:e892372014. View Article : Google Scholar : PubMed/NCBI

32 

Anton L, Olarerin-George AO, Schwartz N, Srinivas S, Bastek J, Hogenesch JB and Elovitz MA: miR-210 inhibits trophoblast invasion and is a serum biomarker for preeclampsia. Am J Pathol. 183:1437–1445. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Pineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, Draghici S, Espinoza J, Kusanovic JP, Mittal P, et al: Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol. 196:261.e1–261.e6. 2007. View Article : Google Scholar

34 

Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K and Williams MA: Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 204:178.e12–178.e21. 2011. View Article : Google Scholar

35 

Muralimanoharan S, Maloyan A, Mele J, Guo C, Myatt LG and Myatt L: miR-210 modulates mitochondrial respiration in placenta with preeclampsia. Placenta. 33:816–823. 2012. View Article : Google Scholar : PubMed/NCBI

36 

Zhang Y, Fei M, Xue G, Zhou Q, Jia Y, Li L, Xin H and Sun S: Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: New insights into molecular mechanisms for the disease. J Cell Mol Med. 16:249–259. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM and Ragoussis J: hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 14:1340–1348. 2008. View Article : Google Scholar : PubMed/NCBI

38 

Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC and Martelli F: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 283:15878–15883. 2008. View Article : Google Scholar : PubMed/NCBI

39 

Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC, et al: MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI

40 

Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI

41 

Grill S, Rusterholz C, Zanetti-Dällenbach R, Tercanli S, Holzgreve W, Hahn S and Lapaire O: Potential markers of preeclampsia-a review. Reprod Biol Endocrinol. 7:702009. View Article : Google Scholar : PubMed/NCBI

42 

Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, Roberts TE, Mol BW, van der Post JA, Leeflang MM, et al: Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 12:1–270. 2008. View Article : Google Scholar

43 

Zakiyah N, Postma MJ, Baker PN and van Asselt AD: IMPROvED Consortium: Pre-eclampsia diagnosis and treatment options: A review of published economic assessments. Pharmacoeconomics. 33:1069–1082. 2015. View Article : Google Scholar : PubMed/NCBI

44 

Poon LC, Stratieva V, Piras S, Piri S and Nicolaides KH: Hypertensive disorders in pregnancy: Combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13 weeks. Prenat Diagn. 30:216–223. 2010.PubMed/NCBI

45 

Poon LC, Maiz N, Valencia C, Plasencia W and Nicolaides KH: First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol. 33:23–33. 2009. View Article : Google Scholar : PubMed/NCBI

46 

Scazzocchio E, Figueras F, Crispi F, Meler E, Masoller N, Mula R and Gratacos E: Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol. 208:203.e1–203.e10. 2013. View Article : Google Scholar

47 

Park FJ, Leung CH, Poon LC, Williams PF, Rothwell SJ and Hyett JA: Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol. 53:532–539. 2013. View Article : Google Scholar : PubMed/NCBI

48 

Akolekar R, Syngelaki A, Poon L, Wright D and Nicolaides KH: Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 33:8–15. 2013. View Article : Google Scholar : PubMed/NCBI

49 

Akolekar R, Syngelaki A, Sarquis R, Zvanca M and Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn. 31:66–74. 2011. View Article : Google Scholar : PubMed/NCBI

50 

Foidart JM, Munaut C, Chantraine F, Akolekar R and Nicolaides KH: Maternal plasma soluble endoglin at 11–13 weeks' gestation in pre-eclampsia. Ultrasound Obstet Gynecol. 35:680–687. 2010.PubMed/NCBI

51 

Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, et al: A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 22:1021–1038. 2009. View Article : Google Scholar : PubMed/NCBI

52 

Lycoudi A, Mavreli D, Mavrou A, Papantoniou N and Kolialexi A: miRNAs in pregnancy-related complications. Expert Rev Mol Diagn. 15:999–1010. 2015. View Article : Google Scholar : PubMed/NCBI

53 

Morales Prieto DM and Markert UR: MicroRNAs in pregnancy. J Reprod Immunol. 88:106–111. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

December 2016
Volume 5 Issue 6

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Munaut, C., Tebache, L., Blacher, S., Noël, A., Nisolle, M., & Chantraine, F. (2016). Dysregulated circulating miRNAs in preeclampsia. Biomedical Reports, 5, 686-692. https://doi.org/10.3892/br.2016.779
MLA
Munaut, C., Tebache, L., Blacher, S., Noël, A., Nisolle, M., Chantraine, F."Dysregulated circulating miRNAs in preeclampsia". Biomedical Reports 5.6 (2016): 686-692.
Chicago
Munaut, C., Tebache, L., Blacher, S., Noël, A., Nisolle, M., Chantraine, F."Dysregulated circulating miRNAs in preeclampsia". Biomedical Reports 5, no. 6 (2016): 686-692. https://doi.org/10.3892/br.2016.779